(Image: Getty/Aramyan)


Strides hamstrung by US FDA Form 483

By Ben Hargreaves

Strides announced that a US FDA inspection of its Bangalore facility has resulted in a Form 483, noting three observations.

(Image: Getty/SeanPastonePhoto)

Takeda to move US base to Boston

By Ben Hargreaves

Takeda will become the latest company to base its operations within Massachusetts, after announcing it would leave its Deerfield, Illinois headquarters.

(Image: Getty/Monsitj)

Five stories that speak volumes about US generics market

By Ben Hargreaves

As Novartis looks to sell a major chunk of its generics portfolio in the US, in-PharmaTechnologist has a look back at some of the stories this year that have signposted larger, on-going trends in the US generics market.

(Image: Getty/gopixa)

European CRO Optimapharm enters US market

By Melissa Fassbender

The Croatia-headquartered contract research organization (CRO) has opened its first office in the US and plans to further expand its footprint organically and through potential acquisitions.

(Image: WuXi AppTec Co., Ltd.)

WuXi AppTec IPO tops $353m

By Melissa Fassbender

The Chinese contract research and development company WuXi AppTec has raised more than $353m in its initial public offering of common stock on the Shanghai Stock Exchange.

(Image: Getty/mthipsorn)

Takeda secures Shire bid for $62.11bn

By Melissa Fassbender

Takeda has acquired Shire for approximately $62.11bn (£46bn) to create a Japan-headquartered biopharmaceutical company with a robust pipeline and expanded geographical footprint.

Follow us


View more